Leerink Partnrs Comments on Tourmaline Bio FY2026 Earnings

Tourmaline Bio, Inc. (NASDAQ:TRML) – Equities researchers at Leerink Partnrs reduced their FY2026 earnings per share estimates for Tourmaline Bio in a note issued to investors on Wednesday, May 21st. Leerink Partnrs analyst T. Smith now anticipates that the company will earn ($4.45) per share for the year, down from their previous forecast of ($4.28). The consensus estimate for Tourmaline Bio’s current full-year earnings is ($3.02) per share. Leerink Partnrs also issued estimates for Tourmaline Bio’s FY2027 earnings at ($5.65) EPS, FY2028 earnings at ($7.45) EPS and FY2029 earnings at ($4.61) EPS.

TRML has been the topic of a number of other reports. Chardan Capital restated a “buy” rating and issued a $70.00 target price on shares of Tourmaline Bio in a report on Monday, May 5th. HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Tourmaline Bio in a research note on Monday, May 5th. Wedbush boosted their price objective on Tourmaline Bio from $42.00 to $43.00 and gave the stock an “outperform” rating in a research report on Friday, March 14th. Finally, Lifesci Capital initiated coverage on Tourmaline Bio in a research report on Monday, February 24th. They set an “outperform” rating and a $58.00 price objective for the company. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tourmaline Bio currently has a consensus rating of “Buy” and an average target price of $49.33.

Tourmaline Bio Price Performance

Shares of Tourmaline Bio stock opened at $15.32 on Monday. The business’s fifty day moving average price is $15.43 and its two-hundred day moving average price is $17.87. The company has a market capitalization of $393.49 million, a P/E ratio of -5.43 and a beta of 2.11. Tourmaline Bio has a 1-year low of $11.56 and a 1-year high of $29.79.

Tourmaline Bio (NASDAQ:TRML) last issued its quarterly earnings results on Friday, May 2nd. The company reported ($0.89) EPS for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.02.

Institutional Investors Weigh In On Tourmaline Bio

Several hedge funds have recently bought and sold shares of TRML. JPMorgan Chase & Co. grew its position in Tourmaline Bio by 16.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 14,804 shares of the company’s stock worth $381,000 after acquiring an additional 2,100 shares during the last quarter. Barclays PLC raised its stake in shares of Tourmaline Bio by 84.0% in the fourth quarter. Barclays PLC now owns 58,566 shares of the company’s stock worth $1,187,000 after purchasing an additional 26,733 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Tourmaline Bio by 4.1% during the fourth quarter. Vanguard Group Inc. now owns 1,106,125 shares of the company’s stock valued at $22,432,000 after acquiring an additional 43,652 shares during the last quarter. American Century Companies Inc. purchased a new stake in shares of Tourmaline Bio during the fourth quarter valued at approximately $474,000. Finally, Swiss National Bank bought a new position in Tourmaline Bio during the fourth quarter valued at $408,000. 91.89% of the stock is currently owned by institutional investors and hedge funds.

About Tourmaline Bio

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.